Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + pegaspargase + dexamethasone + methotrexate
- Development stage
- Phase 2
- Lead developer
- Sun Yat-sen University
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Intramuscular, Oral
01
Overview
The GAD-M regimen is a combination chemotherapy protocol consisting of gemcitabine, pegaspargase, dexamethasone, and high-dose methotrexate. It is being evaluated as a first-line treatment for patients with de novo extranodal NK/T-cell lymphoma (ENKTL). The regimen leverages the synergistic effects of multiple agents: gemcitabine (a nucleoside analog), pegaspargase (an asparagine depletor), dexamethasone (a corticosteroid), and methotrexate (an antifolate). This specific protocol was developed and is being studied by researchers at Sun Yat-sen University to improve outcomes in ENKTL, a rare and aggressive form of non-Hodgkin lymphoma that often shows resistance to conventional anthracycline-based therapies.
- Other names
- GAD-M regimenHigh-dose methotrexate combined with gemcitabine, pegaspargase and dexamethasone
02
Targets
DNADHFR (Dihydrofolate reductase)GR (Glucocorticoid receptor)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + pegaspargase + dexamethasone + methotrexate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + pegaspargase + dexamethasone + methotrexate.